Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized DNA Vaccine in Pediatric Recurrent CNS Tumors
NCT03988283Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2024
- Primary completion
- Mar 2029
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of polyepitope neoantigen dna vaccine in central nervous system tumor, sponsored by Washington University School of Medicine. Primary endpoints: Safety and tolerability of adjuvant personalized neoantigen DNA vaccine at 13 months and Feasibility of adjuvant personalized neoantigen DNA vaccine. Started Oct 2024; status: recruiting.
02
Drugs
polyepitope neoantigen dna vaccine
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT03988283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988283.